Cheng Xiaoliang, Founder and CEO of Pinsen Medical, Named to Fortune China's '40 Under 40' List Amid IPO Filing

On June 22, Fortune (China Edition), one of the world’s most influential business magazines, announced its 2022 list of “China’s 40 Under 40” business elites. Dr. Cheng Xiaoliang, Founder, Chairman, and CEO of Pinsheng Medical, was honored on the list, joining other renowned entrepreneurs such as Zhang Yiming, Founder of ByteDance, and Xu Yangtian, Founder and CEO of SHEIN.

Fortune believes that 2022 was a year of continuous challenges, with the external environment remaining complex: the COVID-19 pandemic had not yet subsided, a new business order was being rebuilt, and the global economy was in urgent need of recovery. However, these factors did not dampen the desire for innovation among China’s young business leaders, who are relying on their wisdom and courage to navigate this unprecedented era of profound change. The honorees of Fortune’s 2022 “China’s 40 Under 40” list operate across various sectors, including artificial intelligence, enterprise services, investment and fintech, new consumption, healthcare and life sciences, intelligent manufacturing, and autonomous driving. They continue to create value, leading transformations in China’s business landscape and even exerting influence on a global scale.

In its profile of Cheng Xiaoliang, Fortune wrote, “Cheng Xiaoliang is among the first generation of researchers in mass spectrometry technology in China, as well as one of the pioneers in proteomics and metabolomics research. The company he founded, Pingsheng Medical, aims to drive innovation in precision medicine with mass spectrometry at its core and multi-omics research as the engine, with the goal of ‘ensuring that everyone benefits from precise diagnosis and treatment.’ By offering a service model that spans the entire clinical mass spectrometry industry chain, Pingsheng Medical provides integrated solutions encompassing omics research services, mass spectrometry instruments and equipment, in vitro diagnostic reagents, and third-party medical laboratory testing. As a technology-driven company, Pingsheng Medical has independently developed internationally leading proteomics and metabolomics research platforms capable of conducting both targeted and untargeted clinical omics studies, thereby supporting the discovery of novel biomarkers and the validation and translation of innovative clinical diagnostic applications. With more than 500 clinical mass spectrometry tests launched, covering areas such as maternal and child health, endocrinology, cardiovascular disease, oncology, neurology, and therapeutic drug monitoring, and including several proprietary precision omics assays, Pingsheng Medical has become one of the leaders in China’s clinical mass spectrometry market.”

It is reported that Fortune has been publishing its “China’s 40 Under 40” list since 2011, aiming to identify young Chinese innovators, value creators, and change-makers. The list is hailed as a “cradle of business superstars,” with notable figures such as Ma Huateng, Ding Lei, and Wang Xing having been featured. (For the full list, please click:"Fortune China's 40 Under 40 Business Elites of 2022"）